Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06425926 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
A Phase 1 study of Solid Tumor and Melanoma Stage IV, sponsored by Georgiamune.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
- 11
- Study locations
NCT06425926 is a Phase 1 study of Solid Tumor and Melanoma Stage IV that is actively recruiting participants, run by Georgiamune. The registered enrollment target is 117 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (47% lower). The trial reports 11 study locations across 8 states.
The verdict
NCT06425926, a Phase 1 study of Solid Tumor and Melanoma Stage IV, is actively recruiting participants, sponsored by Georgiamune.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
- 11
- Study locations
Study Summary
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Conditions Studied
Interventions
- DRUG Anti-PD-1 monoclonal antibody
- DRUG GIM-531
Study Locations (11)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- Providence Medical Foundation - Fullerton
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate - Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Arizona
- HonorHealth Research Institute - Scottsdale
Massachusetts
- Massachusetts General Hospital - Boston
Montana
- Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana - Billings
New York
- Weill Cornell Medicine - New York Presbyterian Hospital - New York
Ohio
- University of Cincinnati Cancer Center - Cincinnati
Tennessee
- Tennessee Oncology, PLLC - Nashville
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06425926
The ClinicalTrials.gov registry entry for NCT06425926 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (47% lower). The listed sponsor is Georgiamune, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Anti-PD-1 monoclonal antibody is the first listed.
NCT06425926 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06425926 about?
NCT06425926 is a clinical study titled "Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors". GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
What is the current status of trial NCT06425926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2024-05-09. Estimated completion is 2026-11.
What conditions does trial NCT06425926 study?
This clinical trial studies the following conditions: Solid Tumor, Melanoma Stage IV.
What interventions are being tested in trial NCT06425926?
The interventions under investigation include: Anti-PD-1 monoclonal antibody (DRUG), GIM-531 (DRUG).
Who is sponsoring clinical trial NCT06425926?
This trial is sponsored by Georgiamune, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06425926 being conducted?
This trial has 11 study locations across Arizona, California, Massachusetts, Montana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.